paroxetine + sodium valproate

Paroxetine + sodium valproate is a combination of two pharmaceutical agents used primarily in the management of comorbid depression and epilepsy, as well as for treatment-resistant depression. Paroxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant that increases synaptic serotonin levels by inhibiting its reuptake, thereby improving mood and anxiety symptoms. Sodium valproate (valproic acid) is an anticonvulsant and mood stabilizer that increases gamma-aminobutyric acid (GABA) levels in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, leading to reduced neuronal excitability. The combination has been shown to provide synergistic effects in animal models, offering protection against chemically induced seizures while also increasing GABA concentrations in key brain regions. This dual action supports its use for patients with coexisting epilepsy and depression or those with treatment-resistant forms of depression[1][2][4].

Brand names

None known as a fixed-dose combination

Other names

paroxetine + sodium valproateparoxetine + valproic acid